Oct. 17, 2023
Soligenix, a late-stage biopharmaceutical company, offers a robust pipeline of multiple fast-track and orphan-designated products with the potential for significant commercial returns of approximately $2 billion in global annual sales. Soligenix's late-stage clinical assets include HyBryteTM or SGX301, a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). The positive statistically significant results achieved in the Phase 3 study of HyBryte have been published in JAMA Dermatology, and the Company is preparing to meet with the FDA to discuss the design of the second confirmatory Phase 3 study. The estimated global market potential for HyBryte is $250 million, making it a significant commercial opportunity in an area of unmet medical need. Visit https://www.redchip.com/stocks/SNGX/ to learn more. https://bit.ly/43TJ8ik
Bloomberg TV Show
CEO Interviews
"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."
1-800-REDCHIP (733-2447) | 431 E Horatio Ave, Suite #100, Maitland, FL 32751
"Discovering Tomorrow's Blue Chips Today." ® | Home | Contact | Privacy Policy | Disclosures
© 2024 RedChip Companies, Inc.